First-in-Human, Dose Finding, Open Label Phase IA-IB Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Summary
The purpose of this phase I trial is to determine the safety of NP-G2-044 among patients with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT03199586
Study ID: NP-G2-044-P1-01
Trial Phase: Phase I
Trial Sponsor: Novita Pharmaceuticals
Therapies Used in This Trial: NP-G2-044